Adamis Pharmaceuticals Corp (ADMP): David J. Marguglio , SR VP of Corporate Development of Adamis Pharmaceuticals Corp sold 4,860 shares on May 4, 2016. The Insider selling transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were sold at $9.17 per share for a total value of $44,576.89 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, David J. Marguglio (SR VP of Corporate Development) sold 1,140 shares at $9.00 per share price.On Aug 17, 2015, Richard C Williams (director) purchased 9,800 shares at $3.26 per share price.Also, On Aug 17, 2015, Robert B Rothermel (director) purchased 7,000 shares at $3.35 per share price.
Adamis Pharmaceuticals Corp: On Wednesday, May 4, 2016 heightened volatility was witnessed in Adamis Pharmaceuticals Corp which led to swings in the share price. The shares opened for trading at $9 and hit $9.31 on the upside , eventually ending the session at $8.97, with a gain of 0.56% or 0.05 points. The heightened volatility saw the trading volume jump to 4,94,222 shares. The 52-week high of the share price is $9.31 and the company has a market cap of $121 M . The 52-week low of the share price is at $3.05.
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is developing various products in the allergy and respiratory markets The Company’s product portfolio includes specialty pharmaceutical products such as Epinephrine pre-filled syringe (PFS) APC-5000 dry powder inhaler (DPI) APC-1000 APC-2000 and APC-3000 and biotechnology products such as TeloB-VAX (vaccine) APC-100 APC-200 and APC-300. The Company’s product candidates for the treatment of asthma and chronic obstructive pulmonary disease (COPD) are APC-5000 DPI and APC-1000. The Company’s other product candidates in its allergy and respiratory product pipeline include APC-1000 APC-3000 and APC-2000. The Company’s drug candidates for the treatment of prostate cancer are APC-100 APC-200 and APC-300. The Company also has a microbicide product candidate named Savvy (C31G). The Company’s product candidate for the treatment of anaphylaxis is Epinephrine PFS.